{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:06:46Z","timestamp":1791166006330,"version":"4.1.0"},"reference-count":120,"publisher":"WHO Press","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bull. World Health Organ."],"published-print":{"date-parts":[[2012,7,1]]},"DOI":"10.2471\/blt.11.097147","type":"journal-article","created":{"date-parts":[[2014,3,27]],"date-time":"2014-03-27T10:37:59Z","timestamp":1395916679000},"page":"540-550","source":"Crossref","is-referenced-by-count":45,"title":["Chronic hepatitis\u00a0C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis"],"prefix":"10.2471","volume":"90","author":[{"given":"Nathan","family":"Ford","sequence":"first","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res, 78 rue de Lausanne, 1211 Geneva, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Kirby","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res, 78 rue de Lausanne, 1211 Geneva, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasha","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, University College Hospital, London, England."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J","family":"Mills","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, University of Ottawa, Ottawa, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Cooke","sequence":"additional","affiliation":[{"name":"Department of Medicine, Imperial College London, London, England."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeeba","family":"Kamarulzaman","sequence":"additional","affiliation":[{"name":"Center of Excellence for Research in AIDS, University of Malaya, Kuala Lumpur, Malaysia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"duCros","sequence":"additional","affiliation":[{"name":"Manson Unit, M\u00e9decins Sans Fronti\u00e8res, London, England."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1305","published-online":{"date-parts":[[2012,2,3]]},"reference":[{"key":"key-10.2471\/BLT.11.097147-201403271131-R1","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1001\/jama.2011.975","article-title":"Hepatitis\u00a0C virus infection and coinfection with human immunodeficiency virus: challenges and advancements in management.","volume":"306","author":"Hadigan","year":"2011","journal-title":"JAMA"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R2","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","article-title":"Global epidemiology of hepatitis\u00a0C virus infection.","volume":"5","author":"Shepard","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R3","unstructured":"Viral hepatitis: global policy. London: World Hepatitis Alliance; 2011. Available from: http:\/\/www.worldhepatitisalliance.org\/Policy\/2010PolicyReport.aspx[accessed 12 January 2012]."},{"key":"key-10.2471\/BLT.11.097147-201403271131-R4","unstructured":"Viral hepatitis. WHA63.18. Sixty-third World Health Assembly. Agenda item 11.12. Geneva: World Health Organization; 2010. Available from: http:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA63\/A63_R18-en.pdf[accessed 12 January 2012]."},{"key":"key-10.2471\/BLT.11.097147-201403271131-R5","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/S0140-6736(06)69374-4","article-title":"Causes of death after diagnosis of hepatitis B or hepatitis\u00a0C infection: a large community-based linkage study.","volume":"368","author":"Amin","year":"2006","journal-title":"Lancet"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R6","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1365-2893.2008.00982.x","article-title":"Cause of death in individuals with chronic HBV and\/or HCV infection, a nationwide community-based register study.","volume":"15","author":"Duberg","year":"2008","journal-title":"J Viral Hepat"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1177\/0962280208094690","article-title":"A population-based record linkage study of mortality in hepatitis\u00a0C-diagnosed persons with or without HIV coinfection in Scotland.","volume":"18","author":"McDonald","year":"2009","journal-title":"Stat Methods Med Res"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jhep.2010.03.015","article-title":"The natural history of hepatitis\u00a0C infection acquired through injection drug use: meta-analysis and meta-regression.","volume":"53","author":"John-Baptiste","year":"2010","journal-title":"J Hepatol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R9","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.jhep.2005.11.009","article-title":"Natural history and predictors of disease severity in chronic hepatitis\u00a0C.","volume":"44","author":"Massard","year":"2006","journal-title":"J Hepatol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.7150\/ijms.3.47","article-title":"The natural history of hepatitis\u00a0C virus (HCV) infection.","volume":"3","author":"Chen","year":"2006","journal-title":"Int J Med Sci"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R11","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis\u00a0C: an update.","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R12","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/hep.22375","article-title":"Estimation of stage-specific fibrosis progression rates in chronic hepatitis\u00a0C virus infection: a meta-analysis and meta-regression.","volume":"48","author":"Thein","year":"2008","journal-title":"Hepatology"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R13","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1093\/cid\/cir076","article-title":"Sustained virologic response to antiviral therapy for chronic hepatitis\u00a0C virus infection: a cure and so much more.","volume":"52","author":"Pearlman","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R14","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ijid.2008.06.042","article-title":"Chronic viral hepatitis may diminish the gains of HIV antiretroviral therapy in sub-Saharan Africa.","volume":"13","author":"Cooper","year":"2009","journal-title":"Int J Infect Dis"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11904-010-0071-3","article-title":"HIV\/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies.","volume":"8","author":"Operskalski","year":"2011","journal-title":"Curr HIV\/AIDS Rep"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R16","unstructured":"Country and lending groups [Internet]. Washington: World Bank; 2011. Available from: http:\/\/data.worldbank.org\/about\/country-classifications\/country-and-lending-groups[accessed 12 January 2012]."},{"key":"key-10.2471\/BLT.11.097147-201403271131-R17","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1214\/aoms\/1177729756","article-title":"Transformations related to the angular and the square root.","volume":"21","author":"Freeman","year":"1950","journal-title":"Ann Inst Stat Math"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/096228029300200202","article-title":"The statistical basis of meta-analysis.","volume":"2","author":"Fleiss","year":"1993","journal-title":"Stat Methods Med Res"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R19","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/humrep\/15.5.1205","article-title":"The need for statistical rigour when pooling data from a variety of sources.","volume":"15","author":"Walters","year":"2000","journal-title":"Hum Reprod"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1471-2288-8-79","article-title":"Undue reliance on I(2) in assessing heterogeneity may mislead.","volume":"8","author":"R\u00fccker","year":"2008","journal-title":"BMC Med Res Methodol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R21","doi-asserted-by":"crossref","unstructured":"Borenstein M, Hedges L, Higgins J, Rothstein H. Meta-regression. In: Borenstein M, Hedges LV, Higgins JPT, Rothstein HR, editors.Introduction to meta-analysis.Chichester: Wiley; 2009. pp.190\u2013202.","DOI":"10.1002\/9780470743386.ch20"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1365-2893.1996.tb00052.x","article-title":"Response to interferon-alpha of Egyptian patients infected with hepatitis\u00a0C virus genotype\u00a04.","volume":"3","author":"El-Zayadi","year":"1996","journal-title":"J Viral Hepat"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R23","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1053\/j.gastro.2008.11.037","article-title":"Improved virologic response in chronic hepatitis\u00a0C genotype\u00a04 treated with nitazoxanide, peginterferon, and ribavirin.","volume":"136","author":"Rossignol","year":"2009","journal-title":"Gastroenterology"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R24","first-page":"80","article-title":"Hepatitis\u00a0C virus genotypes, HLA-DRB alleles and their response to interferon-alpha and ribavirin in patients with chronic hepatitis C.","volume":"4","author":"Jiao","year":"2005","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R25","doi-asserted-by":"publisher","first-page":"358","DOI":"10.4103\/0255-0857.71813","article-title":"Prevalence of hepatitis\u00a0C virus genotypes and impact of T helper cytokines in achieving sustained virological response during combination therapy: a study from central India.","volume":"28","author":"Mishra","year":"2010","journal-title":"Indian J Med Microbiol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R26","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/gene.2011.1","article-title":"IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-alpha plus ribavirin therapy in Taiwanese chronic HCV infection.","volume":"12","author":"Chen","year":"2011","journal-title":"Genes Immun"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R27","first-page":"69","article-title":"Factors influencing the response of interferon therapy in chronic hepatitis C patients.","volume":"21","author":"Ahmed","year":"2011","journal-title":"J Coll Physicians Surg Pak"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R28","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.meegid.2011.04.021","article-title":"High baseline interleukine-8 level is an independent risk factor for the achievement of sustained virological response in chronic HCV patients.","volume":"11","author":"Akbar","year":"2011","journal-title":"Infect Genet Evol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R29","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/1743-422X-8-234","article-title":"Effects of host and virus related factors on interferon-alpha+ribavirin and pegylated-interferon+ribavirin treatment outcomes in chronic hepatitis C patients.","volume":"8","author":"Akram","year":"2011","journal-title":"Virol J"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R30","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/1743-422X-8-258","article-title":"Response to combination therapy of HCV 3a infected Pakistani patients and the role of NS5A protein.","volume":"8","author":"Ali","year":"2011","journal-title":"Virol J"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R31","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1099\/vir.0.018119-0","article-title":"Patient HLA-DRB1* and -DQB1* allele and haplotype association with hepatitis C virus persistence and clearance.","volume":"91","author":"Ali","year":"2010","journal-title":"J Gen Virol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R32","first-page":"983","article-title":"Prevalence of hepatitis C genotypes in Indian patients and their clinical significance.","volume":"49","author":"Amarapurkar","year":"2001","journal-title":"J Assoc Physicians India"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R33","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1365-2893.2007.00946.x","article-title":"Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5.","volume":"15","author":"Antaki","year":"2008","journal-title":"J Viral Hepat"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R34","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1002\/jmv.21641","article-title":"NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: correlation with the response to the combined interferon\/ribavirin therapy.","volume":"81","author":"Bouzgarrou","year":"2009","journal-title":"J Med Virol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R35","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.3748\/wjg.v11.i27.4241","article-title":"Co-infection of SENV-D among chronic hepatitis C patients treated with combination therapy with high-dose interferon-alfa and ribavirin.","volume":"11","author":"Dai","year":"2005","journal-title":"World J Gastroenterol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4103\/0255-0857.62495","article-title":"Infection with hepatitis C virus genotype 3 \u2013 experience of a tertiary health care centre in south India.","volume":"28","author":"David","year":"2010","journal-title":"Indian J Med Microbiol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R37","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.3748\/wjg.v10.i20.2963","article-title":"Impact of cigarette smoking on response to interferon therapy in chronic hepatitis C Egyptian patients.","volume":"10","author":"El-Zayadi","year":"2004","journal-title":"World J Gastroenterol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R38","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1111\/j.1572-0241.2005.00253.x","article-title":"Response of hepatitis C genotype-4 naive patients to 24 weeks of peg-interferon-alpha2b\/ribavirin or induction-dose interferon-alpha2b\/ribavirin\/amantadine: a non-randomized controlled study.","volume":"100","author":"El-Zayadi","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1478-3231.2005.1040.x","article-title":"Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon alpha-2b and ribavirin.","volume":"25","author":"Gallegos-Orozco","year":"2005","journal-title":"Liver Int"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R40","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3748\/wjg.v9.i2.291","article-title":"HCV replication in PBMC and its influence on interferon therapy.","volume":"9","author":"Gong","year":"2003","journal-title":"World J Gastroenterol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R41","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1111\/j.1440-1746.2004.03405.x","article-title":"Treatment of hepatitis C virus infection in patients of northern India.","volume":"19","author":"Hazari","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R42","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1471-230X-9-5","article-title":"A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients.","volume":"9","author":"Idrees","year":"2009","journal-title":"BMC Gastroenterol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R43","first-page":"161","article-title":"Sustained biochemical and virological response of different HCV genotypes to Interferon-alpha plus ribavirin combination therapy","volume":"2","author":"Iqbal","year":"2010","journal-title":"Pharmacologyonline"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R44","first-page":"178","article-title":"Efficacy of triple therapy with interferon alpha-2b, ribavirin and amantadine in the treatment of na\u00efve patients with chronic hepatitis C.","volume":"12","author":"Kalantari","year":"2007","journal-title":"J Res Med Sci"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R45","first-page":"99","article-title":"Interferon-ribavirin treatment in chronic hepatitis C \u2013 the less talked about aspects.","volume":"21","author":"Khalid","year":"2009","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R46","first-page":"473","article-title":"Response to combination therapy in hepatitis virus C genotype 2 and 3.","volume":"19","author":"Khan","year":"2009","journal-title":"J Coll Physicians Surg Pak"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R47","first-page":"5","article-title":"Effectiveness of 48 weeks interferon alfa-2b in combination with ribavirin as initial treatment of chronic hepatitis.","volume":"14","author":"Khokhar","year":"2002","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R48","first-page":"651","article-title":"Outcome of combined interferon-ribavirin in the treatment of chronic hepatitis C.","volume":"14","author":"Muhammad","year":"2004","journal-title":"J Coll Physicians Surg Pak"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R49","first-page":"538","article-title":"Interferon alpha-2b in combination with ribavirin for the treatment of chronic hepatitis C: assessment of virological, biochemical and histological treatment response.","volume":"40","author":"Petrenkiene","year":"2004","journal-title":"Medicina (Kaunas)"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R50","first-page":"480","article-title":"Hepatitis G infection and therapeutic response to interferon in HCV-related chronic liver disease.","volume":"29","author":"Pramoolsinsap","year":"1998","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R51","first-page":"10","article-title":"Response rates to standard interferon treatment in HCV genotype 3a.","volume":"21","author":"Qureshi","year":"2009","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R52","first-page":"460","article-title":"Serum alanine aminotransferase level and response to interferon-ribavirin combination therapy in patients with chronic hepatitis C.","volume":"16","author":"Sarwar","year":"2006","journal-title":"J Coll Physicians Surg Pak"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R53","first-page":"217","article-title":"Treatment failure in chronic hepatitis C: predictors other than viral kinetics.","volume":"35","author":"Sarwar","year":"2010","journal-title":"Rawal Med J"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R54","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3851\/IMP1768","article-title":"Evidence of a significant role for fast-mediated apoptosis in HCV clearance during pegylated interferon plus ribavirin combination therapy.","volume":"16","author":"Schiavon","year":"2011","journal-title":"Antivir Ther"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R55","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.cca.2010.12.009","article-title":"Genetic variation in BCL-2 and response to interferon in hepatitis C virus type 4 patients.","volume":"412","author":"Shaker","year":"2011","journal-title":"Clin Chim Acta"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R56","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1111\/j.1440-1746.2006.04566.x","article-title":"Mutations in ISDR of NS5A gene influence interferon efficacy in Chinese patients with chronic hepatitis C virus genotype 1b infection.","volume":"22","author":"Shen","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R57","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.arcmed.2011.01.001","article-title":"IFN-stimulated gene expression is a useful potential molecular marker of response to antiviral treatment with Peg-IFNalpha 2b and ribavirin in patients with hepatitis C virus genotype 1.","volume":"42","author":"Sixtos-Alonso","year":"2011","journal-title":"Arch Med Res"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R58","first-page":"172","article-title":"Chronic hepatitis C \u2014 treatment results in northern India.","volume":"23","author":"Sood","year":"2002","journal-title":"Trop Gastroenterol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R59","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.3748\/wjg.v12.i24.3821","article-title":"Increased hepatic expression of insulin-like growth factor-I receptor in chronic hepatitis C.","volume":"12","author":"Stefano","year":"2006","journal-title":"World J Gastroenterol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R60","first-page":"243","article-title":"Chronic hepatitis C \u2014 a study of 105 cases between 1990-2000.","volume":"56","author":"Suresh","year":"2001","journal-title":"Med J Malaysia"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R61","first-page":"117","article-title":"Steatosis in hepatitis C virus infection. Response to anti-viral therapy.","volume":"15","author":"Szanto","year":"2006","journal-title":"J Gastrointestin Liver Dis"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R62","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.3748\/wjg.14.2218","article-title":"Sustained virological response based on rapid virological response in genotype-3 chronic hepatitis C treated with standard interferon in the Pakistani population.","volume":"14","author":"Zuberi","year":"2008","journal-title":"World J Gastroenterol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R63","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1097\/MEG.0b013e32833bec1e","article-title":"The H63D genetic variant of the HFE gene is independently associated with the virological response to interferon and ribavirin therapy in chronic hepatitis C.","volume":"22","author":"Carneiro","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R64","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1590\/S1413-86702004000100002","article-title":"Are anti-interferon antibodies the cause of failure in chronic HCV hepatitis treatment?","volume":"8","author":"Barone","year":"2004","journal-title":"Braz J Infect Dis"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R65","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/j.1478-3231.2010.02212.x","article-title":"Natural killer cell receptor and HLA-C gene polymorphisms among patients with hepatitis C: a comparison between sustained virological responders and non-responders.","volume":"30","author":"Carneiro","year":"2010","journal-title":"Liver Int"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R66","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s10620-007-9960-8","article-title":"Response of combination therapy on viral load and disease severity in chronic hepatitis C.","volume":"53","author":"Kumar","year":"2008","journal-title":"Dig Dis Sci"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R67","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1111\/j.1365-2893.2010.01385.x","article-title":"The association of cryoglobulinaemia with sustained virological response in patients with chronic hepatitis C.","volume":"18","author":"Vigani","year":"2011","journal-title":"J Viral Hepat"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R68","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1097\/01.mcg.0000174025.19214.32","article-title":"Gamma-glutamyl transferase (GGT) as an independent predictive factor of sustained virologic response in patients with hepatitis C treated with interferon-alpha and ribavirin.","volume":"39","author":"Villela-Nogueira","year":"2005","journal-title":"J Clin Gastroenterol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R69","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1590\/S1413-86702006000200002","article-title":"Response to treatment with interferon-alpha and ribavirin in patients with chronic hepatitis C virus genotypes 2 and 3 depends on the degree of hepatic fibrosis.","volume":"10","author":"Parise","year":"2006","journal-title":"Braz J Infect Dis"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R70","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1590\/S1413-86702010000500006","article-title":"Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis.","volume":"14","author":"Cheinquer","year":"2010","journal-title":"Braz J Infect Dis"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R71","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.3748\/wjg.v12.i34.5554","article-title":"Efficacy of low dose peginterferon alpha-2b with ribavirin on chronic hepatitis C.","volume":"12","author":"Gupta","year":"2006","journal-title":"World J Gastroenterol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R72","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3851\/IMP1703","article-title":"Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population.","volume":"16","author":"Liao","year":"2011","journal-title":"Antivir Ther"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R73","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1111\/j.1365-2893.2010.01358.x","article-title":"Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV\/HCV-coinfected patients.","volume":"18","author":"Ara\u00fajo","year":"2011","journal-title":"J Viral Hepat"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R74","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.meegid.2011.01.022","article-title":"Evaluation of prognostic factors for peg interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan.","volume":"11","author":"Aziz","year":"2011","journal-title":"Infect Genet Evol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R75","first-page":"207","article-title":"Sustained virological response to pegylated interferon and ribavirin in patients with genotype 3 HCV cirrhosis.","volume":"30","author":"Butt","year":"2009","journal-title":"Trop Gastroenterol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R76","first-page":"223","article-title":"Treatment of hepatitis C with peginterferon and ribavirin in a public health program.","volume":"56","author":"de Almeida","year":"2009","journal-title":"Hepatogastroenterology"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R77","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1594-5804(09)60011-5","article-title":"Evaluation of a novel pegylated interferon alpha-2a (Reiferon Retard\u00ae) in Egyptian patients with chronic hepatitis C - genotype 4.","volume":"3","author":"Esmat","year":"2009;","journal-title":"Digest Liver Dis Suppl"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R78","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1590\/S1413-86702006000500002","article-title":"Weight-based combination therapy with peginterferon alpha-2b and ribavirin for naive, relapser and non-responder patients with chronic hepatitis C.","volume":"10","author":"Gon\u00e7ales","year":"2006","journal-title":"Braz J Infect Dis"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R79","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1177\/135965350701200506","article-title":"Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C.","volume":"12","author":"Males","year":"2007","journal-title":"Antivir Ther"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R80","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/MEG.0b013e3283089392","article-title":"Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon?","volume":"21","author":"Narciso-Schiavon","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R81","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1590\/S0037-86822010000300001","article-title":"Gender influence on treatment of chronic hepatitis C genotype 1.","volume":"43","author":"Narciso-Schiavon","year":"2010","journal-title":"Rev Soc Bras Med Trop"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R82","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1590\/S0036-46652007000200001","article-title":"Cryoglobulinemia in chronic hepatitis C: clinical aspects and response to treatment with interferon alpha and ribavirin.","volume":"49","author":"Parise","year":"2007","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R83","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1590\/S0036-46652009000600004","article-title":"Chronic hepatitis C: hepatic iron content does not correlate with response to antiviral therapy.","volume":"51","author":"Pereira","year":"2009","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R84","first-page":"109","article-title":"Efficacy and tolerability of pegylated interferon alpha 2b and ribavirin in chronic hepatitis C \u2014 a report from eastern India.","volume":"28","author":"Ray","year":"2007","journal-title":"Trop Gastroenterol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R85","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/MCG.0b013e3181bf9b15","article-title":"Treatment of chronic hepatitis C using a 4-week lead-in with nitazoxanide before peginterferon plus nitazoxanide.","volume":"44","author":"Rossignol","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R86","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1590\/S1413-86702007000600006","article-title":"Using pegylated interferon alfa-2b and ribavirin to treat chronic hepatitis patients infected with hepatitis C virus genotype 1: are nonresponders and relapsers different populations?","volume":"11","author":"Silva","year":"2007","journal-title":"Braz J Infect Dis"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R87","first-page":"283","article-title":"Pegylated interferon alfa 2b and oral ribavirin in patients with HCV-related cirrhosis.","volume":"25","author":"Sood","year":"2006","journal-title":"Indian J Gastroenterol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R88","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1155\/2010\/717845","article-title":"Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C.","volume":"24","author":"Taha","year":"2010","journal-title":"Can J Gastroenterol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R89","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1007\/s10620-011-1770-3","article-title":"Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C.","volume":"56","author":"Tohra","year":"2011","journal-title":"Dig Dis Sci"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R90","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1665-2681(19)31653-9","article-title":"Sustained virological response according to the type of early virological response in HCV and HCV\/HIV.","volume":"9","author":"Lerias de Almeida","year":"2010","journal-title":"Ann Hepatol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R91","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1038\/ajg.2010.110","article-title":"Insulin resistance predicts rapid virologic response to peginterferon\/ribavirin combination therapy in hepatitis C genotype 4 patients.","volume":"105","author":"Khattab","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R92","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1002\/jmv.21570","article-title":"Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4.","volume":"81","author":"El Makhzangy","year":"2009","journal-title":"J Med Virol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R93","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1440-1746.2010.06319.x","article-title":"Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy.","volume":"26","author":"Bader el-Din","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R94","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/j.1365-2893.2009.01241.x","article-title":"MxA expression as marker for assessing the therapeutic response in HCV genotype 4 Egyptian patients.","volume":"17","author":"Shaker","year":"2010","journal-title":"J Viral Hepat"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R95","first-page":"341","article-title":"Virological response of Tunisians patients treated by peginterferon plus ribavirin for chronic hepatitis C: a preliminary study.","volume":"86","author":"Belhadj","year":"2008","journal-title":"Tunis Med"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R96","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.dld.2008.09.017","article-title":"IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients.","volume":"41","author":"Chuang","year":"2009","journal-title":"Dig Liver Dis"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R97","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1128\/JCM.00612-08","article-title":"Assessment of specific antibodies to F protein in serum samples from Chinese hepatitis C patients treated with interferon plus ribavirin.","volume":"46","author":"Gao","year":"2008","journal-title":"J Clin Microbiol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R98","first-page":"109","article-title":"Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice.","volume":"14","author":"Gheorghe","year":"2005","journal-title":"Rom J Gastroenterol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R99","first-page":"51","article-title":"High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C.","volume":"18","author":"Gheorghe","year":"2009","journal-title":"J Gastrointestin Liver Dis"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R100","first-page":"23","article-title":"Efficacy, tolerability and predictive factors for early and sustained virologic response in patients treated with weight-based dosing regimen of PegIFN alpha-2b ribavirin in real-life healthcare setting.","volume":"16","author":"Gheorghe","year":"2007","journal-title":"J Gastrointestin Liver Dis"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R101","first-page":"387","article-title":"Nitric oxide levels and sustained virological response to pegylated-interferon alpha2a plus ribavirin in chronic HCV genotype 4 hepatitis: a prospective study.","volume":"19","author":"Ibrahim","year":"2010","journal-title":"J Gastrointestin Liver Dis"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R102","first-page":"306","article-title":"Safety and efficacy of locally manufactured pegylated interferon in hepatitis C patients.","volume":"13","author":"Jabbari","year":"2010","journal-title":"Arch Iran Med"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R103","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1111\/j.1365-2893.2010.01379.x","article-title":"Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy.","volume":"18","author":"Kumthip","year":"2011","journal-title":"J Viral Hepat"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R104","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.antiviral.2011.02.013","article-title":"HCV RNA decline in the first 24 h exhibits high negative predictive value of sustained virologic response in HIV\/HCV genotype 1 co-infected patients treated with peginterferon and ribavirin.","volume":"90","author":"Laufer","year":"2011","journal-title":"Antiviral Res"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R105","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1002\/jmv.21319","article-title":"Efficacy and safety of peginterferon alpha-2a\/ribavirin in treatment-naive Cameroonian patients with chronic hepatitis C.","volume":"80","author":"Njouom","year":"2008","journal-title":"J Med Virol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R106","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1665-2681(19)31678-3","article-title":"Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of peg-interferon - ribavirin in daily practice.","volume":"9","author":"Ridruejo","year":"2010","journal-title":"Ann Hepatol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R107","first-page":"637","article-title":"Pegylated interferon alfa-2b (peg-intron) plus ribavirin (rebetol) in the treatment of chronic hepatitis C: a local experience.","volume":"60","author":"Seow","year":"2005","journal-title":"Med J Malaysia"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R108","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12157-010-0213-7","article-title":"Chronic hepatitis C: epidemiology, diagnosis and treatment in Yalgado-Ouedraogo teaching hospital in Ouagadougou.","volume":"5","author":"Sombie","year":"2011","journal-title":"J Afr Hepato Gastroenterol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R109","first-page":"261","article-title":"Outcome of antiviral treatment in patients with chronic genotype 1 HCV hepatitis: a retrospective study in 507 patients.","volume":"19","author":"Sporea","year":"2010","journal-title":"J Gastrointestin Liver Dis"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R110","first-page":"798","article-title":"Persistent transaminase elevations in chronic hepatitis C patients with virological response during peginterferon and ribavirin therapy.","volume":"56","author":"Su","year":"2009","journal-title":"Hepatogastroenterology"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R111","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1111\/j.1478-3231.2009.02080.x","article-title":"Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus.","volume":"29","author":"Yu","year":"2009","journal-title":"Liver Int"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R112","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1111\/j.1440-1746.2007.04904.x","article-title":"Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.","volume":"22","author":"Yu","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R113","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1365-2893.2010.01373.x","article-title":"Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a.","volume":"18","author":"Zhou","year":"2011","journal-title":"J Viral Hepat"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R114","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/MCG.0b013e3181775e6a","article-title":"Is the rapid virologic response a positive predictive factor of sustained virologic response in all pretreatment status genotype 1 hepatitis C patients treated with peginterferon-alpha2b and ribavirin?","volume":"43","author":"de Segadas-Soares","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R115","doi-asserted-by":"crossref","first-page":"153","DOI":"10.17305\/bjbms.2010.2715","article-title":"Characteristics of chronic hepatitis C among intravenous drug users: a comparative analysis.","volume":"10","author":"Jovanovi\u0107","year":"2010","journal-title":"Bosn J Basic Med Sci"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R116","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/hep.23504","article-title":"Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials.","volume":"51","author":"Awad","year":"2010","journal-title":"Hepatology"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R117","unstructured":"Swan T.The hepatitis C treatment pipeline report. New York: Treatment Action Group; 2011. Available from: http:\/\/www.treatmentactiongroup.org\/uploadedFiles\/About\/Publications\/TAG_Publications\/2011\/HCV%20pipeline%202011%20final.pdf[accessed 12 January 2012]."},{"key":"key-10.2471\/BLT.11.097147-201403271131-R118","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1473-3099(09)70041-6","article-title":"Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis.","volume":"9","author":"Orenstein","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R119","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/nrgastro.2011.49","article-title":"A new standard of care for the treatment of chronic HCV infection.","volume":"8","author":"Hofmann","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"key-10.2471\/BLT.11.097147-201403271131-R120","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nrd3214","article-title":"Excitement grows for potential revolution in hepatitis C virus treatment.","volume":"9","author":"Opar","year":"2010","journal-title":"Nat Rev Drug Discov"}],"container-title":["Bulletin of the World Health Organization"],"original-title":[],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T17:10:12Z","timestamp":1742404212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3397704\/pdf\/BLT.11.097147.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,3]]},"references-count":120,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2012,2,3]]},"published-print":{"date-parts":[[2012,7,1]]}},"URL":"https:\/\/doi.org\/10.2471\/blt.11.097147","relation":{},"ISSN":["0042-9686"],"issn-type":[{"value":"0042-9686","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2,3]]}}}